Article Dans Une Revue Lung Cancer Année : 2024

Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study

1 CHRU Tours - Centre Hospitalier Régional Universitaire de Tours
2 UT - Université de Tours
3 Département cancer environnement (Centre Léon Bérard - Lyon)
4 COMPO - Méthodes computationnelles pour la prise en charge thérapeutique en oncologie : Optimisation des stratégies par modélisation mécaniste et statistique
5 IMM - Institut du Thorax Curie Montsouris [Paris]
6 UNICANCER/CRLC - Centre Régional de Lutte contre le Cancer François Baclesse [Caen]
7 UNICANCER/ICO - Institut de Cancérologie de l'Ouest [Angers/Nantes]
8 CRCI2NA - Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes-Angers
9 IAB - Institute for Advanced Biosciences / Institut pour l'Avancée des Biosciences (Grenoble)
10 CHUGA - CHU de Grenoble-Alpes - Centre Hospitalier Universitaire CHU Grenoble
11 UPCité - Université Paris Cité
12 CIC 1425 - Centre d'investigation Clinique [CHU Bichat] - Épidémiologie clinique
13 RESHAPE - Inserm U1290 - UCBL1 - Research on Healthcare Performance
14 HCL - Hospices Civils de Lyon
15 CHBA - Centre hospitalier Bretagne Atlantique (Morbihan)
16 Hôpital Foch [Suresnes]
17 Service Pneumologie / Allergologie [CHU Clermont-Ferrand]
18 Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou]
19 OSS - Oncogenesis, Stress, Signaling
20 CRC (UMR_S_1138 / U1138) - Centre de Recherche des Cordeliers
21 CHU Nantes - Centre Hospitalier Universitaire de Nantes = Nantes University Hospital
22 INCIT - Immunology and New Concepts in ImmunoTherapy
23 IFCT - Intergroupe Francophone de Cancérologie Thoracique [Paris]
24 CHRU Besançon - Centre Hospitalier Régional Universitaire de Besançon
25 CANTHER - Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277
José Hureaux
Luc Odier
  • Fonction : Auteur
Clotilde Descarpentries

Résumé

Background: Capmatinib is a selective MET inhibitor with demonstrated efficacy in a phase II study of non-small cell lung cancer (NSCLC) patients harboring METex14 mutations. However, the real-world outcomes of capmatinib are largely unknown. From June 2019, the French Early Access Program (EAP) provided capmatinib to METex14 NSCLC patients who were ineligible for or for whom first-line standard therapies had failed. Methods: IFCT-2104 CAPMATU was a multicenter study that included all METex14 NSCLC patients who received capmatinib as part of the EAP until August 2021. The primary endpoints were time to treatment failure (TTF), progression-free survival (PFS), overall survival (OS) and objective response rate (ORR). Results: A total of 146 patients were included. The median age was 74.9 years, 56.6 % were never-smokers, and 32.4 % had brain metastases. The median TTF, median PFS and median OS from capmatinib initiation were 5.1 months (95 % CI 4.2-6.0), 4.8 months (95 % CI 4.0-6.0) and 10.4 months (95 % CI 8.3-13.2), respectively. Evaluation of the best response to capmatinib was available for 134 patients and resulted in an ORR of 55.3 % (95 % CI 46.8 %-63.6 %). The median PFS was 7.7 months for treatment-naïve patients and 6.0 and 4.1 months for patients who had received one or 2 + prior lines of treatment, respectively. For patients with brain metastases, the median PFS was 3.0 months. Capmatinib had a known and manageable safety profile, with grade 3 to 4 adverse events, mostly peripheral edema (8.2 %), occurring in 17.8 % of patients. Conclusion: In this large real-world study of METex14 NSCLC patients, the efficacy of capmatinib was confirmed, with a manageable safety profile, even in patients with brain metastases and in those who received several lines of treatment. This study reinforces the key role of capmatinib for these patients.

Fichier non déposé

Dates et versions

hal-05033907 , version 1 (14-04-2025)

Identifiants

Citer

Marion Ferreira, Aurélie Swalduz, Laurent Greillier, Pauline Du Rusquec, Hubert Curcio, et al.. Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study. Lung Cancer, 2024, 196, pp.107934. ⟨10.1016/j.lungcan.2024.107934⟩. ⟨hal-05033907⟩
48 Consultations
0 Téléchargements

Altmetric

Partager

  • More